3-p-tolyloxyphenol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-p-tolyloxyphenol
• 英文别名: 3-(4-Tolyloxy)-phenol；3-(p-tolyloxy)phenol；3-(4-Methylphenoxy)phenol
• 化学式: C₁₃H₁₂O₂
• 分子量: 200.237
• InChiKey: SCFCSDBZMDPIGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-p-tolyloxyphenol 在 吡啶 、 potassium carbonate 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 {5-[3-(3-p-tolyloxyphenoxy)propoxy]-1H-indol-3-yl}acetic acid methyl ester
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of a series of alkoxy-3-indolylacetic acids as peroxisome proliferator-activated receptor γ/δ agonists

  摘要：

  A series of alkoxy-3-indolylacetic acid analogs has been discovered as peroxisome proliferator-activated receptor (PPAR) agonists. Structure-activity relationship study indicated that PPAR alpha/gamma/delta activities were dependent on the nature of the hydrophobic group, the attachment position of the alkoxy linker to the indole ring, and N-alkylation of indole nitrogen. Some compounds presented significant PPAR gamma/delta activity and molecular modeling suggested their putative binding modes in the ligand binding domain of PPAR gamma. Of these, compound 51 was selected for in vivo study via an evaluation of microsomal stability in mouse and human liver. Compound 51 lowered the levels of fasting blood glucose, insulin, and HbA1c without gain in body weight in db/db mice. When compound 51 was treated, hepatic triglycerides level and the size of adipocytes in white adipose tissue of db/db mice were also reduced as opposed to treatment with rosiglitazone. Taken together, compound 51 shows high potential warranting further studies in models for diabetes and related metabolic disorders and may be in use as a chemical tool for the understanding of PPAR biology. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.04.046
• 作为产物：
  描述：

  3-(4-Tolyl)oxy-phenol O-benzyl ether 在 palladium dihydroxide N2 、 ammonium formate 作用下， 以 乙醇 、 正己烷 、 乙酸乙酯 为溶剂， 以185 mg (45%)的产率得到3-p-tolyloxyphenol
  参考文献：
  名称：

  Substituted aromatic ethers as inhibitors of glycine transport

  摘要：

  这项发明涉及一系列符合以下式I1的取代芳香醚，其中环A和X和Y的定义如规范中所述，它们表现出作为甘氨酸转运抑制剂的活性，它们的药学上可接受的盐、含有它们的药物组合物，以及它们用于增强认知和治疗哺乳动物，包括人类，的精神分裂症和其他精神病的正性和负性症状。

  公开号：

  US20030013887A1

文献信息

• INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
  申请人：Dumas Jacques

  公开号：US20120046290A1

  公开（公告）日：2012-02-23

  This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.

  本发明涉及一组芳香脲在治疗细胞因子介导的疾病（除癌症外）和蛋白水解酶介导的疾病（除癌症外）中的用途，以及用于此类治疗的药物组合物。
• Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
  申请人：Miller Scott

  公开号：US20080269265A1

  公开（公告）日：2008-10-30

  This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

  这项发明涉及使用一组芳基脲类化合物治疗raf介导的疾病，以及用于该疗法的药物组合物。
• INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS
  申请人：Dumas Jacques

  公开号：US20070244120A1

  公开（公告）日：2007-10-18

  Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

  治疗由raf激酶介导的肿瘤的方法，包括使用取代脲化合物，以及这些化合物本身。
• SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES
  申请人：Bouey Edith

  公开号：US20100004159A1

  公开（公告）日：2010-01-07

  The present invention relates to polysubstituted imidazolone derivatives, to the pharmaceutical compositions comprising them and to the therapeutic uses thereof in the human and animal health fields. The present invention also relates to a process for preparing these derivatives.

  本发明涉及多取代咪唑酮衍生物，包括它们的药物组合物以及在人类和动物健康领域中的治疗用途。本发明还涉及一种制备这些衍生物的方法。
• [EN] NOVEL GLUCOCORTICOID RECEPTOR AGONISTS<br/>[FR] NOUVEAUX AGONISTES DU RÉCEPTEUR DES GLUCOCORTICOÏDES
  申请人：PFIZER LTD

  公开号：WO2010136940A1

  公开（公告）日：2010-12-02

  This invention relates to novel glucocorticoid receptor agonists of formula (I) and to processes and intermediates for their preparation. The present invention also relates to pharmaceutical compositions containing these compounds, to their combination with one or more other therapeutic agents, as well as to their use for the treatment of a number of inflammatory and allergic diseases, disorders and conditions.

  本发明涉及一种新型的化学式（I）的糖皮质激素受体激动剂，以及用于它们的制备的过程和中间体。本发明还涉及含有这些化合物的药物组合物，以及它们与一个或多个其他治疗剂的联合使用，以及它们用于治疗多种炎症和过敏性疾病、紊乱和症状。